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Nowadays prostate cancer is the most common solid tumor in men from industrialized countries and the second leading cause
of death. At the ages when PCa is usually diagnosed, mortality related to cardiovascular morbidity is high; therefore, men at risk
for PCa frequently receive chronic lipid-lowering and antiplatelet treatment. The aim of this study was to analyze how chronic
treatment with statins, aspirin, and their combination influenced the risk of PCa detection. The tumorigenic properties of these
treatments were evaluated by proliferation, colony formation, invasion, andmigration assays using different PCa cell lines, in order
to assess how these treatments act at molecular level. The results showed that a combination of statins and aspirin enhances the
effect of individual treatments and seems to reduce the risk of PCa detection (OR: 0.616 (95%CI: 0.467–0.812), P < 0.001). However,
if treatments are maintained, aspirin (OR: 1.835 (95% CI: 1.068–3.155), ! = 0.028) or the combination of both drugs (OR: 3.059
(95% CI: 1.894–4.939), ! < 0.001) represents an increased risk of HGPCa. As observed at clinical level, these beneficial effects in
vitro are enhanced when both treatments are administered simultaneously, suggesting that chronic, concomitant treatment with
statins and aspirin has a protective effect on PCa incidence.
1. Introduction
Nowadays prostate cancer (PCa) is the most common solid
tumor in men from industrialized countries and the second
leading cause of death [1, 2]. For this reason, the discovery of
modifiable risk determinants would provide an opportunity
to prevent or delay the onset of this common disease.
Established risk factors, such as ancestry or family history, are
not modifiable, and the evidence for dietary and lifestyle risk
factors is inconclusive [3].
At the ages when PCa is usually diagnosed, mortality
related to cardiovascular morbidity is high [4]. Associations
between coronary heart disease and PCa risk have even been
suggested [5]; men at risk of PCa frequently receive chronic
lipid-lowering and antiplatelet treatment [6, 7]. Statins and
aspirin are two of the most frequently used drugs, and they
both have been implicated in prostate carcinogenesis, albeit
not without some controversy [8, 9].
Statins (3-hydroxy-3-methyl-glutaryl-coenzyme A redu-
ctase inhibitors) are the most commonly used drugs for
Hindawi Publishing Corporation
BioMed Research International
Volume 2015, Article ID 762178, 11 pages
http://dx.doi.org/10.1155/2015/762178
2 BioMed Research International
Table 1: Characteristics of study groups.
Nontreated cells Statins Aspirin Statin + aspirin
Men (") 1504 440 160 304
Age (years) 67 68 68 67
BMI (Kg/m2) 26.9 27.6 27.2 27.8
Serum PSA (ng/mL) 6.9 6.7 6.9 6.8
Positive DRE (%) 540 (36) 160 (36) 50 (31) 106 (35)
Gleason score < 7 (%) 112 (7.4) 32 (7.3) 14 (8.8) 18 (6)
Gleason score = 7 (%) 273 (18.2) 76 (17.3) 38 (23.8) 45 (14.8)
Gleason score > 7 (%) 155 (10.3) 43 (9.8) 18 (11.2) 24 (7.9)
BMI: body mass index, PSA: prostate specific antigen, and DRE: digital rectal examination.
lowering cholesterol [10]. In recent years, a growing amount
of evidence on the anticancer effects of statins has become
available from laboratory and epidemiological studies. In
vitro and in vivo studies [11] suggest that statins are able to
arrest cell cycle progression [12], induce apoptosis [13], reduce
inflammation, and impede angiogenesis [14].
Currently, observational studies support that statin users
have an unchanged overall risk of PCa; however, some well-
designed epidemiological studies have reported a reduced
incidence of advanced PCa in this population. Moreover,
statins showed an inhibitory effect on the growth of PCa in
both in vitro and in vivo studies [15]. On the other hand,
in recent years the role of inflammation in cancer etiology
has gained attention, and several studies have suggested that
nonsteroidal anti-inflammatory drugs (NSAIDs) may have
chemopreventive activity. NSAIDs have been associated with
a reduced risk of detection for different malignancies: a
reduction of the relative risk of 63% for colorectal cancer,
39% for breast cancer, 36% for lung cancer, and up to 39% for
PCa [16]. In particular, the use of acetyl salicylic acid (ASA),
the active metabolite of aspirin and a well-known NSAID, is
associated with a 15%–55% risk reduction for PCa [17–20];
however, two other studies associated aspirin with increased
risk of PCa [21, 22], while others reported no association
[23, 24]. Although some controversy exists, the protective
effect of aspirin treatment is reinforced by a recent meta-
analyses study that showed a decreased overallmortality from
cancer in a population using a continuous low dose of aspirin
daily. This effect increased according to the treatment time
[25]. This effect could be related to the potential role of the
inflammation pathway in the development of PCa.
There are many studies based on the influence of statins
and aspirin on PCa risk. However, even though it is common
clinical practice [26], there is no report describing how a
chronic treatment combining both treatments influences the
risk of PCa detection.Therefore, the aim of our study was to
analyze how the chronic treatment with statins, aspirin, and
their combination influenced the risk of PCa detection in a
cohort of patients undergoing prostate biopsy (PB) due to
elevated prostate specific antigen (PSA) or abnormal digital
rectal examination (DRE). We also evaluated the effect of
these treatments on tumorigenic properties using different
PCa cell lines, in order to corroborate clinical observations
at in vitro level.
2. Materials and Methods
2.1. Design. We conducted a retrospective case-control study
at a single academic center. All participants received detailed
information about the study procedure and provided written
informed consent before study entry. All procedures were
in accordance with the ethical standards established in our
country. Internal review board approval was not required for
such a nonexperimental study.
2.2. Patients. Between January 2006 and December 2011,
2,408 consecutive Mediterranean men, who had been
referred for prostate biopsy due to abnormal DRE and/or
serum PSA levels higher than 4 ng/mL, were included in this
study.
A total of 1,830 men (76%) were undergoing their first
PB, while, for 578 of them, it was a repeat PB procedure.
All patients were assessed by anamnesis about cardiovascular
comorbidities and risk factors, life style (smoking habit and
physical activity), and pharmacological treatments. A total
of 1,504 men (62.5%) had not been treated with statins or
aspirin, while 440 of them (18.3%) had been treated with
statins, 160 (6.6%) with aspirin, and 304 (12.6%) with a
combination of statins and aspirin. All of the men who
received prior treatment had received it chronically for
more than 1 year when this study began, and no significant
differences existed among the groups, either in the initial PSA
levels, in DRE results, or in the Gleason scores (see Table 1).
2.3. Prostatic Biopsy Technique. The PB was done as an
ambulatory procedure with local anesthesia. An end-fire
ultrasound transducer (Falcon 2101, B-K Medical, Inc.) and
a 16-gauge automatic biopsy needle (Bard, Inc.) were used to
perform the biopsy. At least 10 cores, plus 2 to 8 additional
ones, according to age and prostate volume, were obtained,
according to a modified Vienna nomogram [27].
2.4. Cell Culture. All cell lines were obtained from the
American Type Culture Collection (Rockville, MD). PCa
cell lines PC3 (isolated from bone metastasis of human
prostate carcinoma) and LNCaP (established from a biopsy
of a lymph node metastasis of hormone refractory PCa)
were maintained in RPMI 1640 medium (Life Technologies,
Inc., Grand Island, NY) supplemented with 10% fetal bovine
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serum (FBS), 2mM l-glutamine, 100U of penicillin/mL,
100 #g of streptomycin/mL, and 0.1mM nonessential amino
acids. Cells were grown at 37∘C in an atmosphere of 5%CO2-
95% air and 99% humidity.
2.5. Drug Concentrations. Doses of the drugs used in this
study were chosen based on previous studies by Murtola
et al. [28], where, moreover, the same prostate cancer cell
lines were used. Standard doses of simvastatin (STA) have
been reported to obtain a peak serum value in the range
of 10–100 nM; a concentration slightly above the therapeutic
range had been chosen for this study (1 #M) (Sigma-Aldrich).
Acetylsalicylic acid (ASA) (Sigma-Aldrich) was used at a
concentration of 1mM based on common plasma salicylate
levels with therapeutic doses of aspirin [29].
2.6. Proliferation Analysis. A number of 5 × 104 cells per well
were seeded on six-well plates with the appropriate medium.
The cells were allowed to attach and were subsequently
treated with the indicated drugs (STA, ASA, or STA + ASA)
for 7 days, renewing growth medium and treatments daily.
Cells were counted by using Neubauer chamber.
2.7. Colony Formation Assay. For the colony formation assay,
cells were seeded at low density (250 cells/well in a 12-well
plate) and were allowed to grow for 10 days, renewing growth
medium and treatments every 2 days. Then, the cells were
fixed in paraformaldehyde 4% and stained with crystal violet.
Colony formation was quantified by OD reading at 590 nm
after 2-hour extraction of the crystal violet stain.
2.8. Migration Assays
Wound Healing. The PC3 cells were allowed to reach con-
fluent monolayer in 24-well plates and were incubated
overnight. A straight line (wound)was then gently performed
at the bottom of the dish with a 0.5mm plastic pipette
tip. Afterwards, cells were washed, incubated in medium
with 2% FBS, with or without treatments, and kept in
a computer controlled mini-incubator, which provided a
stabilized temperature of 37∘C with 95% humidity, 5% CO2,
and optical transparency for microscopic observations. The
incubator was fastened to an inverted microscope (Live Cell
Imaging CellR, Olympus, Japan) to monitor cell migration.
Images were taken with the 4x objective every 30 minutes at
predetermined wound sites (3 sites per condition, performed
in triplicate) and were analyzed using the Image J software
(Wright Cell Imaging Facility, USA). Initial wound area
(#m2) and time needed to close the wound (hr) were the
variables used to calculate the migration speed of the cells.
Transwell Migration Assay. LNCaP cells were seeded (105
cells/insert) onto transwell inserts (BDBioscience, USA)with
8 #m diameter pore membranes in medium supplemented
with 2% FBS in the presence or absence of treatments.
After 48 hours, cells from inserts were fixed with 4%
paraformaldehyde (PFA) and stained with 0.1% crystal violet.
Migration was quantified by OD reading at 590 nm after 2-
hour extraction of the crystal violet stain.
2.9. Transwell Matrigel Invasion Assay. PCa cells were seeded
(104/insert) onto Matrigel Invasion Chamber inserts (BD
Bioscience, USA) with 8#m diameter pore membranes in
triplicate in medium supplemented with 2% FBS in the
presence or absence of treatments and with the lower cham-
ber containing medium supplemented with 10% FBS. After
48 hours, the number of invading cells was determined as
described above (transwell migration assay).
2.10. Western Immunoblotting. Cultured cells, washed with
cold PBS, were scratched with RIPA buffer (Tris 20mM
pH 8.8, NaCl 150mM, EDTA 5mM, Triton X-100 1%, and
protease inhibitors) and supernatant boiled at 100∘C for
5min with Laemmli buffer.The same amount of protein was
resolved by 10% SDS-PAGE and transferred onto a PVDF
membrane (Immobilon PSQ,Millipore,Massachusetts, USA).
Membranes were blocked in TBS with 5% nonfat dried milk
and 0.1%Tween 20 for 1 h prior to incubation at 4∘Covernight
with the appropriate primary antibody (1 : 200 %2-integrin,
Santa Cruz Biotechnology, Santa Cruz, CA, USA; 1 : 400
cyclin D1, Santa Cruz Biotechnology, Santa Cruz, CA, USA;
1 : 50 vimentin, Sigma-Aldrich, Saint Louis, Missouri, USA;
1 : 2000E-cadherin, BDTransduction Laboratories, PaloAlto,
CA, USA; 1 : 1000 %-tubulin, Sigma-Aldrich, Saint Louis,
Missouri, USA). Detection was done using horseradish-
peroxidase-conjugated secondary antibodies and enhanced
chemiluminescence reagents (Amersham ECL, GE Health-
care, Buckinghamshire, UK).
2.11. Statistical Analysis. Quantitative variables were express-
ed as medians, interquartile range, and range. Qualitative
variables were expressed as percentages. Mann-Whitney U
test, Wilcoxon test, and Kruskal-Wallis test were used to eval-
uate the significance of differences, comparing quantitative
variables in two or more groups. Chi-square and Cochran
tests were used to assess the normal distribution of patients,
according to categorical variables and their correlation. A
multivariate analysis through a binary logistic regression was
performed to detect independent PC or HGPCa predictors.
Odds ratios and 95% confidence interval were estimated.
All analyses were calculated using SPSS v.20 (IBM, Inc.)
statistical software. Statistical analysis of the cell culture data
was performed by means of one-way analysis of variance
(ANOVA) (Tukey’s posttest).
3. Results
3.1. Observational Clinical Study. Once the final diagnosis
was obtained, PCa was detected in 848 of the 2,408 patients
included in this study (35.2%), 240 of whom presented with
high grade PCa (HGPCa) (28.3%).
The distribution of PCa and, specifically, the HGPCa
cases in relation to aspirin and statins treatments is shown in
Table 2. Among the 1,504 nontreated men, PCa was detected
in 552 (36.7%) without statistical differences when compared
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Table 2: Distribution of patients according to the diagnosis of PCa and HGPCa and the treatment with statins, aspirin, and the combination
of both treatments.
PCa detection (%) ! value HGPCa detection (%) ! value
Nontreated cells 552/1504 (37) — 136/552 (24.6) —
Statins 152/440 (34.5) 0.879 40/152 (26.3) 0.673
Aspirin 64/160 (40) 0.536 24/64 (37.5) 0.034
Statins + aspirin 80/304 (26.3) 0.003 40/80 (50) <0.001
Table 3: Multivariate analysis of PC risk and HGPCa risk according to the treatment with statins and aspirin respect no treatment.
Treatment PCa detection∗ ! value HGPCa detection∗ ! value
Age (years) 1.066 (1.049–1.084) 0.001 1.100 (1.071–1.130) 0.001
BMI (Kg/m2) 1.018 (0.001–1.047) 0.189 0.989 (0.948–1.032) 0.616
PSA (ng/mL) 1.024 (1.008–1.041) 0.004 1.038 (1.027–1.049) 0.001
DRE (positive versus negative) 1.219 (1.028–1.428) 0.001 1.266 (0.879–1.822) 0.205
Statin (yes versus no) 0.910 (0.728–11.137) 0.430 1.092 (0.725–1.646) 0.637
Aspirin (yes versus no) 1.150 (0.824–1.604) 0.439 1.835 (1.068–3.155) 0.028
Statins + aspirin (yes versus no) 0.616 (0.467–0.812) <0.001 3.059 (1.894–4.939) <0.001
Time on statins (months) 0.998 (0.955–1.000) 0.063 1.005 (1.000–1.010) 0.034
Time on aspirins (months) 0.984 (0.979–0.990) <0.001 1.033 (1.020–1.047) <0.001
BMI: body mass index, PSA: prostate specific antigen, and DRE: digital rectal examination. ∗Values expressed as odds ratio (95% confidence interval).
to men who were only treated with statins or those who were
only treated with aspirin. In the statin-only subset, PCa was
detected in 152 of 440 patients (34.5%) (! value = 0.879), and
in the aspirin-only subset 64PCa cases were detected (40%)
(! value = 0.536). Interestingly, in the group of 304 patients
that received concomitant treatment with statins and aspirin,
PCa was detected in significantly fewer cases (26.3%) when
compared to the nontreated group (! value = 0.003).
Regarding the rate of PCa patients who presented with
HGPCa, we observed that, in the nontreated group, 24.6% of
the PCa patients presented with HGPCa (136/552), whereas
the aspirin group presented a significantly higher incidence
rate of HGPCa, 37.5% (24/64) (! value = 0.034).This increase
was especially noted in men who had been administrated the
concomitant treatment with statins and aspirin, achieving a
rate of 50% (40/80) (! value < 0.001). On the other hand,
no statistical difference was observed in PCa patients treated
with statins withHGPCa cases having a rate of 26.3% (! value
= 0.673).
After the analysis of the above results, a binary logistic
regression was conducted to evaluate if the treatment with
statins and aspirin could be an independent predictor of the
PCa risk and HGPCa incidence. Age, serum PSA, DRE and
bodymass index (BMI), statins, aspirin, and the combination
between statins and aspirin treatments as well as the duration
of those were included as predictive variables in this analysis
(Table 3). As expected, age and serum PSA were PCa predic-
tors.The reduction in overall PCa incidence was statistically
significant for current users of both drugs. Statins and aspirin
used as chronic concomitant treatment were an independent
predictor factor of reduction of PCa detection risk, OR: 0.616
(95% CI: 0.467–0.812), ! < 0.001.
Regarding the risk of high grade tumors detection, treat-
mentwith aspirin,OR: 1.835 (95%CI: 1.068–3.155),! = 0.028,
and combined therapy, OR: 3.059 (95% CI: 1.894–4.939), ! <0.001, were independent factors of HGPCa. Furthermore, the
length of aspirin treatment was a significant predictor of PCa,
OR: 0.998 (95% CI 0.979–0.990), ! < 0.001, while the length
of statins treatment, OR: 1.005 (1.000–1.010), ! = 0.034, and
aspirin, OR: 1.033 (1.020–1.047), ! < 0.001, was a predictor of
HGPCa.
3.2. In Vitro Effects of Simvastatin, Acetylsalicylic Acid, and
Their Combination. Considering the clinical observations
that have been mentioned above, STA and ASA were used
to treat different PCa cell lines, in order to unveil by
which mechanisms the chronic treatment with these drugs
significantly decreased the PCa incidence.
3.2.1. Effect on the Proliferation of Prostatic Cancer Cells.
Firstly, after 7 days of treatment the effects of STA, ASA,
and their combination on proliferation were studied in PC3
and LNCaP PCa cell lines. The results showed a significant
decrease in the proliferation rate of PC3 treated with STA
(62%; ! value = 0.001) and with the combination of both
(68%; ! value < 0.001); however, no effects were observed
due to the presence of ASA in the culture media compared
to control cells (cells treated only with DMSO). On the other
hand, only the combination of STA and ASA was able to
markedly reduce the proliferation in LNCaP cells (90%; !
value = 0.002) (Figures 1(a)-1(b)).
To further study the effect of these treatments on the cell
cycle, we analyzed the levels of cyclinD1 protein, a key protein
in regulation of cell cycle. As expected, cyclin D1 showed a
significant decrease in protein levels in those groups in which
we also obtained a most marked decrease in cell proliferation
(Figures 1(c)-1(d)).
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Figure 1: Effect of STA, ASA, and the combination of both treatments on prostate cancer cell lines proliferation. Values for proliferation are
presented as number of cells (∗106) after 7 days of treatment for (a) PC3 and (b) LNCaP cell lines with different conditions: nontreated cells,
control (C) and control with DMSO (C(DMSO)), and cells treated with statin (STA), aspirin (ASA), and a combination of both statin and
aspirin (STA + ASA) (for further details, see Section 2).The bars represent the mean ± SEM. Values that are significantly different by one-way
analysis of variance (ANOVA) from the C(DMSO) group are indicated by ∗! < 0.05, ∗∗∗! < 0.001. Western blots of cyclin D1 (37KDa) and
the control %-tubulin (52KDa) performed on total cell extracts after 7 days of treatment are presented for PC3 (c) and LNCaP (d) cell lines.
Densitometry analysis using Image J software is represented below bands as fold change values (versus C(DMSO)).
3.2.2. Effect on Colony Formation Capacity. PC3 cells were
grown at low cell density (250 cells/well) in the absence or
presence of the indicated concentration of STA, ASA, and
the combination of both STA and ASA for 10 days. PC3
cells formed colonies, as described by others [30]; however
LNCaP cells did not show the same ability to grow from so
low cell density. Regarding treatment effects, long-term ASA
treatment inhibited cell colony formation ability compared
to control cells which had been receiving DMSO in 36%
(! value < 0.001); furthermore, this effect was even higher
in those cells treated with STA (91%; ! value < 0.001)
and the combination of both drugs (98%; ! value < 0.001)
(Figure 2).
3.2.3. Effect on Migration and Invasion Capacity. In addition
to cell growth and proliferation, cell mobility was studied
as an important step in tumor progression; therefore, we
analyzed the invasion and migration abilities of PC3 and
LNCaP cells.
First, using transwell assay the invasion capacity was
assessed on PC3 and LNCaP cell lines. The number of PC3
that migrated to the bottom of the transwell chambers sig-
nificantly decreased compared to the nontreated group (cells
with DMSO) after being treated for 48 h with ASA (48%) and
STA + ASA (48%) (Figures 3(a) and 3(c)). Unexpectedly, no
evident changes were found for LNCaP invasiveness (Figures
3(b) and 3(d)).
Second, the migration ability of both tumoral cell lines
was analyzed by using wound-healing assays in PC3 line
because of their ability to form a monolayer and transwell
assay in LNCaP. STA and the combination of STA and ASA
caused significant inhibition of PC3migration after 48 h (61%
and 57%, resp.) (Figure 4(a)) as these treatments do not allow
the cells to close the wound (Figure 4(c)). On the contrary, no
effect for the different treatments was observed in LNCaP cell
lines (Figure 4(b)).
The lethal consequences of HGPCa are related to its
metastasis to other organ sites, especially bones. Epithelial-
to-mesenchymal transition (EMT) has received considerable
attention as a paradigm to explain invasive and metastatic
behavior during PCa progression as well as other tumors.
Cells undergoing EMT lose their epithelial morphology,
reorganize their cytoskeleton, and acquire amotile phenotype
through the up- and downregulation of several molecules
including tight and adherent junctions proteins and mes-
enchymal markers [31]. Bearing this in mind, the final aim
of the present investigation was to see which proteins could
be related to these effects on cell invasion and migration.The
levels of some of those proteins, which play an important
role during EMT, were analyzed (%2-integrin, vimentin,
and E-cadherin for PC3 and %2-integrin for LNCaP). The
results showed that, after 7 days of treatment with ASA
and the combination of STA and ASA, the levels of %2-
integrin increased slightly in PC3 cells. In the case of LNCaP,
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Figure 2: Effect of STA, ASA, and the combination of both treat-
ments on PC3 cell line colony formation capacity. Values for colony
formation capacity are presented as crystal violet absorbance/well
after 10 days of treatment for PC3 cell line with different conditions:
nontreated cells, control (C) and control with DMSO (C(DMSO)),
and cells treatedwith statin (STA), aspirin (ASA), and a combination
of both statin and aspirin (STA + ASA) (for further details, see
Section 2). (a) The bars represent the mean ± SEM. Values that are
significantly different by one-way analysis of variance (ANOVA)
from the C(DMSO) group are indicated by ∗∗! < 0.01, ∗∗∗! <0.001. (b) An inverted microscope with phase contrast at 10x
magnification was used to take images of stained colonies.
%2-integrin slightly increased in cells treated with ASA and
increased more markedly with the combination of both
treatments compared to the control cells (Figures 3(c) and
3(d)).On the other hand, no changewas observed in the other
proteins analyzed.
4. Discussion
PCa predominantly affects older men, who are likely to have
comorbidities, such as cardiovascular conditions, that often
indicate treatment with aspirin and statins. This find is in
keeping with some authors, who have reported a significant
correlation between PCa and coronary disease prevalence [5]
as well as the fact that cardiovascular events are usually the
first cause of death in patients with PCa [4].
In the last years some publications on this field investi-
gated the relation between the uptake of statins and aspirin
and PCa incidence; however, the impact of chronic treatment
with statins and aspirin in prostate carcinogenesis is contro-
versial. In 2008, a meta-analysis that included 6 randomized
trials, 6 cohort studies, and 6 case-control studies concluded
that there was neither association between statin therapy
and PCa risk nor the time of treatment administration [9].
However, other studies observed a protective effect of statins
on diagnosing PCa in advanced stages [9]. A similar study,
where 4,202men who had undergone PB were analyzed [32],
showed that 24% of the patients that had been treated with
statins at the time of PB presented a PCa detection rate of
45% compared to 42% in those patients who had not received
statins. Furthermore, the Gleason score was 7 or higher in
72%of the tumors detected in chronic statins users compared
to 62% in those patients not using this drug. However, the
rate of patients with a Gleason score 8 or higher in radical
prostatectomy specimens was 14% in both groups.This study
did not take into account treatment with aspirin. With the
same objective, Murtola et al. [33] analyzed the impact of
statins in a series of 23,320men (28%of them received statins)
who underwent PSA screening between 1996 and 2004. The
authors concluded that this treatment reduced the overall
incidence of PCa, even after removing the bias produced by its
effect on serum PSA. Moreover, they observed an association
between time of statins therapy and the risk of PCa detection,
without any relation to tumor aggressiveness. This study
also monitored the use of other drugs, such as aspirin (17%
of patients) and other potential confounders of PCa risk,
which did not change the benefit of statins. However, the
impact of combination therapy with statins and aspirin was
not analyzed in this study. Aspirin has been associated with
a reduced risk of PCa by some authors, while others have
questioned this correlation. The chemopreventive effect of
aspirin and other nonsteroidal anti-inflammatory drugs has
been reported in recent data. This effect ranges from 10 to
55% [17, 18, 20, 34–37]. A recent meta-analysis that included
24 studies, 9 case controls with 5,795 men, and 15 cohorts
with 31,657 patients has suggested a chemopreventive effect
of aspirin on PCa [38].
With the aim of clarifying these controversial studies,
we conducted a clinical observational study on 1,504 men
undergoing PCa screening. Our study shows that more than
a third of the population at screening of PCa was receiving
some treatment to prevent cardiovascular disease. Specifically
in this cohort, around 38% were chronic patients with 48%
receiving statins, 18% receiving aspirin, and 34% receiving
both drugs.
We observed that the detection rates of PCa in patients
treated with statins or aspirin were statistically similar to
the rate observed in patients who were not receiving any of
these drugs. However, the detection rate of PCa observed
in patients that were treated simultaneously with statins and
aspirin was significantly lower (! value = 0.003). Further-
more, with relation to histological grade, our study suggests
that chronic treatment with aspirin could be an independent
predictor of HGPCa detection as well as the combination
therapy with statins and aspirin. This is because, according
to our analysis, there was a higher incidence of HGPCa in
chronic aspirin (! value = 0.034) users or men receiving
concomitant treatment (! value < 0.001).
This is not the first time that an epidemiological study
has related the increase of HGPCa tumors in chronic users
of aspirin [38]. However, other authors have found an inverse
correlation between aspirin and HGPCa rates [39, 40].
Besides that, some studies have shown that statins are able
to decrease serum PSA levels [41]. This could be considered
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Figure 3: Effect of STA, ASA, and the combination of both treatments on prostate cancer cell lines invasion capacity. Values for invasion are
presented as crystal violet absorbance/well for PC3 (a) and LNCaP (b) cell lines after 48 h of treatment with different conditions: nontreated
cells, control (C) and control with DMSO (C(DMSO)), and cells treated with statin (STA), aspirin (ASA), and a combination of both statin
and aspirin (STA + ASA) (for further details, see Section 2). The bars represent the means ± SEM. Values that are significantly different by
one-way analysis of variance (ANOVA) from the control (C = nontreated) group are indicated by ∗! < 0.05 (versus C(DMSO)). Western blot
of %2-integrin (150KDa), vimentin (58KDa), E-cadherin (120KDa), and the control %-tubulin (52KDa) was performed on total cell extracts
after 7 days of treatment for PC3 cell line (c) and %2-integrin (150KDa) and the control %-tubulin (52KDa) for LNCaP (d). Densitometry
analysis using Image J software is represented below bands as fold change values (versus C(DMSO)).
as one possible explanation that could clarify the controversy
on the effect of statins in PCa detection. The serum PSA
level directly impacts the indication for PB [42, 43], and it
may cause a masking bias on the possible protective effect of
statins, since a population subgroup would not have biopsy
criterion. In this case, the treatments may decrease the risk
of PCa but also delay the diagnosis, which could explain the
increased detection of HGPCa.
The present study had some limitations, which were
also common in several other studies, where the effects of
statins and aspirin were evaluated, for example, not being a
prospective study or the effect of statins in the serum PSA
hindering the evaluation of the influence of this drug in PCa.
Then, there is the idea of the chronic treatment concept or not
analyzing each drug dose separately, which would not allow
us to draw distinct conclusions.
As a secondary objective, the tumorigenic properties of
statins and aspirin on different PCa cell lines were studied, as
a way to better understand our clinical observations. Thus,
taking into account the results obtained in vitro in which
the proliferation decreased dramatically as well as colony
formation capacity after treating the cells with STA and ASA,
we were able to hypothesize that statins and aspirin do have
antitumoral effects in PCa, as other authors have observed
previously [44–46]. Specifically, it could be that either aspirin
treatment alone and/or simultaneous treatmentmay enhance
the preventive effect of statins on prostate carcinogenesis
at the expense of an increase in the detection of HGPCa.
As we mentioned before, we have seen a direct effect of
statins on proliferation, which can probably be explained
by a marked decrease of cyclin D1 levels. The combination
of both treatments could enhance this effect. These results,
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Figure 4: Effect of STA, ASA, and the combination of both treatments on prostate cancer cell lines invasion capacity. Values for PC3 cell line
migration capacity (a) are presented as the difference between the wound-healing speed (#m2/h) before and after 48 h of treatment calculated
using Image J software and values for LNCaP migration (b) are presented as crystal violet absorbance/well after 48 h of treatment. Both cell
lines were treated with different conditions: nontreated cells, control (C) and control with DMSO (C(DMSO)), and cells treated with statin
(STA), aspirin (ASA), and a combination of both statin and aspirin (STA + ASA) (for further details, see Section 2). The bars represent the
mean ± SEM. Values that are significantly different by one-way analysis of variance (ANOVA) from the C(DMSO) group are indicated by∗∗∗! < 0.001. (c) Phase contrast 10x images from migration mode during wound-healing assay at 48 h after treatment for PC3 cell line.
in addition to those based on the significant effect of the
three treatments being higher when the cells received a
concomitant treatment and on colony formation capacity,
could be related to clinical observations of patients referred
for PB and the incidence of PCa.
The mechanism by which statins influence prostate car-
cinogenesis could be mediated by the reduction of serum
cholesterol and, consequently, by a decrease of intraprostatic
dihydrotestosterone levels. Prostate tissues lose homeostatic
control over cholesterol levels with age [47]. This effect
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could explain the observed differences in the results for each
cell line used in our study because, as it is well known,
PC3 prostate cancer cells are hormone independent and
LNCaP prostate cancer cells are hormone dependent and
these propertiesmay influence the cell line response although
several studies would be needed to clarify this question.
The overall consequence of this cholesterol accumulation on
prostate physiology is unknown, but a role for high levels of
serum cholesterol in PCa incidence and progression has been
suggested by a number of epidemiological and preclinical
studies [10–14, 48].
In order tofind an explanation for the increased incidence
of HGPCa in patients treated chronically with aspirin and
simultaneously with statins and aspirin, we should perform
more extensive studies. However, in cancer, it is known
that the expression of integrins, which are involved in cell
adhesion, is frequently altered, leading to cell proliferation,
migration, and metastasis. Previous studies have shown that
integrin expression levels were correlated to the different
stages of human cancer progression [49–51], and it has
also been suggested that %2-integrin may be a metastasis
suppressor [50]. In contrast, in PCa, %2-integrin was found
to induce PCa cell metastasis to the bone [51, 52]. Therefore,
integrin function is cell type and context dependent. Keeping
in mind what we obtained, a moderate increase of these
protein levels in vitro after ASA and concomitant treatment
of STA and ASA in PC3 cell line, it could be related to
those patients with a higher incidence of HGPCa. On the
other hand, after performing invasion and migration assays
on both PCa cell lines, the concomitant treatment seemed to
present antitumorigenic effects. No changes in vimentin and
E-cadherin were observed in vitro,whichmakes us think that
the decrease in migration might not be related to changes in
phenotype EMT.Therefore, a different approach is necessary
to clarify the role of integrin and how other proteins could be
implicated in the positive properties of statins and aspirin in
PCa and HGPCa.
5. Conclusions
Although only a randomized, prospective trial that controls
for patient age, comorbidities, adjuvant treatments, and dose
stratification will prove the benefits of statins and aspirin
treatment, the collection of all of the results presented in
this study suggests that chronic concomitant treatment with
statins and aspirin does have a protective effect for PCa
incidence. Statins and aspirin have antitumorigenic prop-
erties, and these beneficial effects are enhanced when both
treatments are administered simultaneously.
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